Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial – LUNG CANCER

-Ares, LP; Goto, Y; Lim, DWT; Halmos, B; Cho, BC; Cobo, M; Larriba, JLG; Zhou, CC; Demedts, I; Atmaca, A; Baka, S; Mookerjee, B; Portella, S; Zhu, ZW; Wu, JC; Demanse, D; Dharan, B; Reck, M – 2024 – 10.1016/j.lungcan.2023.107451

Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer – JOURNAL FOR IMMUNOTHERAPY OF CANCER

Molina-Alejandre, M; Perea, F; Calvo, V; Martinez-Toledo, C; Nadal, E; Sierra-Rodero, B; Casarrubios, M; Casal-Rubio, J; Martinez-Martí, A; Insa, A; Massuti, B; Viteri, S; Aranda, IB; Rodriguez-Abreu, D; de Castro, J; Martínez, JM; Cobo, M; Wistuba, II; Parra, ER;...

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden A Nonrandomized Controlled Trial – JAMA ONCOLOGY

Provencio, M; Ortega, AL; Coves-Sarto, J; Calvo, V; Marsé-Fabregat, R; Dómine, M; Guirado, M; Carcereny, E; Fernández, N; Alvarez, R; Blanco, R; León-Mateos, L; Sánchez-Torres, JM; Sullivan, IG; Cobo, M; Sánchez-Hernández, A; Massuti, B; Sierra-Rodero, B;...

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 – ANNALS OF ONCOLOGY

Besse, B; Felip, E; Campelo, RG; Cobo, M; Mascaux, C; Madroszyk, A; Cappuzzo, F; Hilgers, W; Romano, G; Denis, F; Viteri, S; Debieuvre, D; Galetta, D; Baldini, E; Razaq, M; Robinet, G; Maio, M; Delmonte, A; Roch, B; Masson, P; Schuette, W; Zer, A; Remon, J;...